The Novor team is going back to China attending two prestige conferences, PEGS China in Shanghai (March 28 – 30) and International Congress of Antibodies (ICA2017) in Beijing (March 29 – 31).
Our co-founder and CEO, Mingjie, will give a talk at ICA2017 on March 30. He will briefly talk about the antibody protein sequencing and then share our vision on the future of the technology. Mingjie is also invited to the High-Level Talks between Entrepreneurs panel discussion, where senior executives from several fast-growing biotech and biopharma companies will discuss the challenges and opportunities in the biopharmaceutical market and share their company’s strategy in the next three years.
Our co-founder and CTO, Qixin and our Sales & Business Development Manager, Anthony, will show case our sequencing technology in Shanghai. Have a discussion with them at booth #7 and see how this technology can help you in your current research projects.
We are packing up some refreshing mints and chargers with us. Come grab some freebies and discuss some science!
Newsletter for All Things Protein Sequencing
Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics